Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion.


Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 27 05 2019
revised: 17 10 2019
accepted: 05 11 2019
pubmed: 26 11 2019
medline: 4 8 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

The increase of plasma levels of high-density lipoproteins and Apolipoprotein A-I (ApoA-I), its main protein component, has been shown to have a positive action on glucose disposal in type 2 diabetic patients. The current study investigates the unexplored function of ApoA-I to prime beta cells for improved insulin secretion. INS-1E rat clonal beta cells as well as isolated murine islets were used to study the effect of ApoA-I on responsiveness of the beta cells to high glucose challenge. Confocal and transmission electron microscopy were used to dissect ApoA-I mechanisms of action. Chemical endocytosis blockers were used to understand the role of ApoA-I internalization in mediating its positive effect. Pre-incubation of beta cells and isolated murine islets with ApoA-I augmented glucose stimulated insulin secretion. This effect appeared to be due to an increased reservoir of insulin granules at the cell membrane, as confirmed by confocal and transmission electron microscopy. Moreover, ApoA-I induced pancreatic and duodenal homeobox 1 (PDX1) shuttling from the cytoplasm to the nucleus, with the subsequent increase in the proinsulin processing enzyme protein convertase 1 (PC1/3). Finally, the blockade of ApoA-I endocytosis in beta cells resulted in a loss of ApoA-I positive action on insulin secretion. The proposed mechanisms of the phenomenon here described include ApoA-I internalization into beta cells, PDX1 nuclear translocation, and increased levels of proinsulin processing enzymes. Altogether, these events lead to an increased number of insulin granules.

Identifiants

pubmed: 31765698
pii: S0925-4439(19)30336-9
doi: 10.1016/j.bbadis.2019.165613
pii:
doi:

Substances chimiques

APOA1 protein, human 0
Apolipoprotein A-I 0
Homeodomain Proteins 0
Insulin 0
Lipoproteins, HDL 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

165613

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Oktawia Nilsson (O)

Lund Institute of Advanced Neutron and X-ray Science (LINXS), Lund, Sweden.

Rita Del Giudice (R)

Lund Institute of Advanced Neutron and X-ray Science (LINXS), Lund, Sweden.

Mototsugu Nagao (M)

Department of Clinical Sciences, Lund University, Malmö, Sweden.

Caitriona Grönberg (C)

Lund Institute of Advanced Neutron and X-ray Science (LINXS), Lund, Sweden.

Lena Eliasson (L)

Department of Clinical Sciences, Lund University, Malmö, Sweden.

Jens O Lagerstedt (JO)

Lund Institute of Advanced Neutron and X-ray Science (LINXS), Lund, Sweden; Lund Institute of Advanced X-ray and Neutron Science (LINXS), Lund, Sweden. Electronic address: jens.lagerstedt@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH